Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.
Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.
The findings of the KEYNOTE-002 study presented Sunday at the Society for Melanoma Research (SMR) 2014 International Congress marked another important result for pembrolizumab. Marketed as Keytruda by Merck, the monoclonal antibody targeting PD-1 received accelerated FDA approval in early September for patients with metastatic melanoma whose disease has progressed on prior therapies.1
Adil Daud, MD, of the University of California at San Francisco, underscored that limited treatment options are available for patients with melanoma whose disease has progressed on ipilimumab or BRAF inhibitors.
In the 3-arm phase 2 study, patients received pembrolizumab at 2 mg/kg (n = 180), 10 mg/kg (n = 181), or chemotherapy (n = 179). At 6 months, the progression-free survival (PFS) rates were 34% and 38% for the 2 mg/kg and 10 mg/kg doses, respectively. Compared with chemotherapy, the lower dose demonstrated a 43% improvement in PFS and the 10 mg/kg dose showed a 50% improvement. The study was designed with co-primary endpoints to assess PFS and overall survival (OS). OS data are anticipated in 2015.2
Given the response rates with pembrolizumab, Dr Daud called this a “highly positive study.” He noted that no significant difference was noted in response between the 2 dose levels. Of note, he said, patients who stayed on pembrolizumab for a longer time showed lower toxicity. No Grade 4 adverse events were seen.
He pointed out that the overall response rate was 5 to 6 times higher with pembrolizumab over chemotherapy. “The benefit from pembrolizumab was seen regardless of BRAF status,” Dr Daud said.
Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Multiple clinical trials are currently underway exploring pembrolizumab across a variety of tumor types, including a phase 2 and 3 study investigating the agent for advanced melanoma. At this point, over 30 studies are exploring the drug.2
References
1. FDA approves Keytruda for advanced melanoma [press release]. Silver Spring, MD: FDA newsroom; September 4, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm41280htm.
2. Inman S. Pembrolizumab improves PFS ORR versus chemotherapy in Phase II melanoma study. Onclive. http://www.onclive.com/web-exclusives/Pembrolizumab-Improves-PFS-ORR-Versus-Chemotherapy-in-Phase-II-Melanoma-Study. Published November 16, 2014.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More